Internal Medicine, Hematology & Oncology · Little Rock, AR
NPI
1598747164
Since 2005
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
8901 Carti Way
Little Rock, AR, 72205
Phone (501) 219-8777
Groups this clinician bills Medicare through
Medicare paid, 2024
$9.0M
474,799 services
Medicare patients, 2024
1,470
Average age 74
Drug cost, 2024
$15.5M
4,364 prescriptions
Company payments, 2025
$81.2
From 4 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Kamal Patel was code J9299 (injection, nivolumab, 1 mg), 41,960 times for 19 patients. In total Kamal Patel billed 474,799 services in 235 codes, and Medicare paid $9.0M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-03-30.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9299 Injection, nivolumab, 1 mg | Office | 41,960 | 19 | $24.59 | $1.0M |
| J9271 Injection, pembrolizumab, 1 mg | Office | 41,200 | 42 | $44.63 | $1.8M |
| Q5125 Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram | Office | 35,340 | 23 | $0.38 | $13K |
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 24,480 | 24 | $0.28 | $6,811 |
| J9263 Injection, oxaliplatin, 0.5 mg | Office | 21,700 | 19 | $0.06 | $1,236 |
| J9025 Injection, azacitidine, 1 mg | Office | 15,100 | 15 | $0.30 | $4,591 |
| J0185 Injection, aprepitant, 1 mg | Office | 15,080 | 41 | $1.34 | $20K |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 15,000 | 84 | $6.26 | $94K |
| J9267 Injection, paclitaxel, 1 mg | Office | 14,930 | 25 | $0.08 | $1,174 |
| J0897 Injection, denosumab, 1 mg | Office | 11,940 | 77 | $20.54 | $245K |
| J9022 Injection, atezolizumab, 10 mg | Office | 10,920 | 17 | $66.73 | $729K |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 10,900 | 89 | $15.74 | $172K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 10,475 | 179 | $0.09 | $940 |
| J9264 Injection, paclitaxel protein-bound particles, 1 mg | Office | 8,900 | 11 | $10.72 | $95K |
| J0461 Injection, atropine sulfate, 0.01 mg | Office | 5,475 | 26 | $0.06 | $350 |
By year: 2022 $9.3M for 623,525 services; 2023 $9.6M for 570,340 services; 2024 $9.0M for 474,799 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 3,754 | 909 | $8.64 | $32K |
| 85025 Blood Count | 3,207 | 689 | $7.56 | $24K |
| 80053 Clinical Chemistry | 3,032 | 862 | $10.30 | $31K |
| 88185 Surgical Pathology Examination | 1,357 | 53 | $15.49 | $21K |
| 82728 Clinical Chemistry | 1,323 | 535 | $13.29 | $18K |
| 82784 Immunoassay | 1,217 | 211 | $9.08 | $11K |
| 83540 Clinical Chemistry | 873 | 404 | $6.32 | $5,515 |
| 83550 Clinical Chemistry | 864 | 401 | $8.54 | $7,378 |
| 86334 Immunoassay | 399 | 203 | $21.85 | $8,716 |
| 84165 Clinical Chemistry | 396 | 201 | $10.51 | $4,164 |
Medicare prescription drug claims, 2024
In 2024, the drug Kamal Patel prescribed most often to Medicare patients was Eliquis (Apixaban), with 251 prescriptions and refills. In total Kamal Patel wrote 4,364 Medicare prescriptions that cost $15.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Eliquis Apixaban | 251 | 300 | 39 | $168K |
| Darzalex Daratumumab | 245 | 245 | 12 | $2.2M |
| Letrozole Generic | 211 | 329 | 34 | $2,775 |
| Xarelto Rivaroxaban | 196 | 259 | 31 | $142K |
| Prednisone Generic | 196 | 220 | 67 | $1,287 |
| Ondansetron Odt Ondansetron | 195 | 195 | 92 | $3,508 |
| Neulasta Onpro Pegfilgrastim | 171 | 171 | 41 | $1.1M |
| Promethazine Hcl Generic | 167 | 167 | 72 | $1,074 |
| Mvasi Bevacizumab-Awwb | 139 | 139 | 16 | $828K |
| Hydroxyurea Generic | 107 | 150 | 16 | $1,961 |
| Procrit Epoetin Alfa | 102 | 102 | 30 | $297K |
| Gabapentin Generic | 97 | 104 | 18 | $829 |
| Anagrelide Hcl Generic | 84 | 98 | Under 11 | $4,529 |
| Tecentriq Atezolizumab | 71 | 71 | Under 11 | $758K |
| Potassium Chloride Generic | 71 | 91 | 23 | $1,031 |
Brand drugs: - claims; generic drugs: 2,299 claims; opioid claims: 92.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Kamal Patel $81.2 ($81.2 in general payments such as food, travel and fees) from 4 companies. The largest payer was Blueprint Medicines Corporation with $20.85.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.